MIDLOTHIAN, Va., Oct. 28 /PRNewswire/ -- Today, PARI Respiratory Equipment presented a comparative study of three commercially available, breath-enhanced nebulizers and their in-vitro performance and delivery efficiency of budesonide inhalation suspension (Pulmicort Respules, AstraZeneca). Conclusions from the in-vitro study show that the LC Sprint Reusable Nebulizer delivered the shortest treatment times, with an average of 4.9 minutes, and had the highest respirable drug delivery rate.
"We found that drug delivery differs between commercially available nebulizers, something for clinicians to consider when contemplating whether patients receive clinically effective doses," said Lisa Cambridge, director of clinical development for PARI Respiratory Equipment, Inc. "Since patient compliance may be associated with the speed of treatment and delivery efficiency, this study highlights key differences between nebulizers."
The study compares the LC Sprint Reusable Nebulizer (PARI Respiratory Equipment), LC PLUS Reusable Nebulizer (PARI Respiratory Equipment), and Sidestream Plus reusable nebulizer (Respironics). Ms. Cambridge presented the results today at CHEST 2008, the annual meeting of the American College of Chest Physicians.
Key conclusions showed:
-- Respirable drug delivery rate (RDDR) was the highest with LC Sprint Reusable Nebulizer -- in fact, RDDR is 46% higher for LC Sprint Reusable Nebulizer compared to Sidestream Plus
-- Respirable dose is similar with LC Sprint and LC PLUS, though RDDR was 25% higher for LC Sprint Reusable Nebulizer
-- Respirable dose and RDDR for LC PLUS Reusable Nebulizer demonstrate higher delivery efficiency (33% and 39% respectively) than Sidestream Plus
-- Treatment times were shortest with LC Sprint Reusable Nebulizer (4.9 minutes)
These conclusions draw upon results from an American Thoracic Society
poster (Keller M et al., 2002) that show higher respirable drug delivery
|SOURCE PARI Respiratory Equipment, Inc.|
Copyright©2008 PR Newswire.
All rights reserved